Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresenius Kabi AG

www.fresenius-kabi.com

Latest From Fresenius Kabi AG

Fresenius Delivers First US Biosimilar Approval

Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.

Biosimilars Approvals

Keeping Track: US FDA Novel Approvals Return With Xenpozyme, Spevigo Nods; Stimufend Survives COVID-19 Delays

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Drug Review

Fresenius Files Tocilizumab Biosimilar With EMA

Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.

Biosimilars Europe

Fresenius Kabi Breaks Into Brazilian Biosimilars Market

Fresenius Kabi has struck a deal with Brazilian organizations Fiocruz/Bio-Manguinhos and Bionovis to supply its Idacio biosimilar adalimumab rival to Humira for the next ten years.

Deals Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
  • Other Names / Subsidiaries
    • mAbxience S.L.
UsernamePublicRestriction

Register